Financial Data and Key Metrics Changes - The company reported a strong overall growth of 33% in genomics volume, with oncology growing at 27% and hereditary testing at 37% [4] - Positive adjusted EBITDA was achieved for the first time, marking a significant milestone after 10 years of efforts [5] - The company expects to be slightly positive in adjusted EBITDA for the year, despite additional expenses from the Paige acquisition [5] Business Line Data and Key Metrics Changes - The data licensing or insights business grew by 38% in the quarter, contributing an additional $150 million in total contract value [4] - The genomic growth was broad-based, with all assays performing exceptionally well [4] Market Data and Key Metrics Changes - The company noted that testing volumes have been healthy as more biomarkers are identified, contributing to the overall growth in the genomics market [10] - The average reimbursement for the third quarter was $1,600, which is still below parity with peers [30] Company Strategy and Development Direction - The company aims for sustained long-term unit growth and revenue growth, targeting about 25% growth for the next three years [15] - The integration of digital pathology with genomic diagnostics is expected to enhance sequencing capabilities and improve patient outcomes [61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the hereditary business, expecting it to grow in the low to mid-20s range [35] - The company is well-positioned to benefit from future reimbursement changes in the healthcare system, particularly for data interpretation and analysis [52] Other Important Information - The foundation model is progressing well, with expectations to enter the post-training phase later this year and have the first versions ready by Q1 2026 [46] - The company is actively investing in AI and cloud computing to enhance its technological capabilities [47] Q&A Session Summary Question: What is driving the strong growth in the oncology portfolio? - The growth is attributed to a more efficient sales force and the integration of technology that provides comprehensive results to physicians [9][10] Question: How is the company planning to market MRD testing? - The company plans to gradually increase market presence as reimbursement becomes available, leveraging a well-trained sales force [17] Question: Can you provide details on the $150 million in new contracts? - The company highlighted that these contracts are multi-year deals and do not directly translate to immediate revenue increases [21][22] Question: How does Ambry's growth compare to the broader market? - Ambry's growth is primarily driven by share gains, and the company expects its growth to moderate in Q4 [34] Question: What updates can you provide on the foundation model with AstraZeneca and Pathos? - The foundation model is in the pretraining phase, with positive progress and expectations for the first versions to be ready in early 2026 [46] Question: How does the company view the potential for reimbursement of data interpretation? - Management believes that reimbursement for data interpretation will eventually be necessary for scaling, positioning the company well for future growth [52]

Core Insights - DeepTempo, a leader in behavioral threat detection using deep learning, will collaborate with Cribl at the CrowdStrike Fal.Con 2025 event in Las Vegas [1] - The DeepTempo team will demonstrate their foundation model, LogLM, which is designed to counter AI-enabled adversaries and enhance enterprise defense against modern threats [1] Company Overview - DeepTempo specializes in behavioral threat detection, leveraging advanced deep learning techniques [1] - Key personnel from DeepTempo include CEO Evan Powell and Director of Product Management Craig Stancill [1] Event Participation - DeepTempo will be present at CrowdStrike Fal.Con 2025, providing insights on their technology and its integration with the Cribl platform [1] - The event serves as a platform for DeepTempo to showcase how their solutions can help enterprises navigate contemporary security challenges [1]

Financial Data and Key Metrics Changes - Revenue increased by 89.6% to $314.6 million, with Genomics revenue rising 115% to $241.8 million driven by volume growth in oncology [4][5] - Quarterly gross profit reached $195 million, reflecting a 160% increase, while adjusted EBITDA improved from negative $16 million to negative $5.6 million [5][6] - Full year 2025 revenue guidance was raised to $1.26 billion, with an adjusted EBITDA forecast of approximately $5 million, indicating a $110 million improvement over the previous year [6] Business Line Data and Key Metrics Changes - Genomics revenue growth was primarily attributed to oncology volume growth, which increased from 20% to 26% [4] - Data and Services revenue grew by 35.7% to approximately $73 million, led by a 41% increase in data licensing from Incyte [5] Market Data and Key Metrics Changes - Significant sequential volume growth was observed across the entire oncology testing compendium, with hereditary volumes also exceeding expectations [12][14] - The company is capturing market share from historical players who have reduced their presence in the market, indicating strong tailwinds in the overall space [15] Company Strategy and Development Direction - The company is focused on maintaining growth while approaching adjusted EBITDA breakeven, with plans to continue investing in growth opportunities [6][43] - There is a strong emphasis on AI and data integration into diagnostics, with expectations that this will transform R&D portfolios and patient care [49][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth, highlighting the importance of long-term strategies over short-term gains [97] - The company anticipates that reimbursement for MRD (Minimal Residual Disease) testing will occur in 2026, which is expected to significantly boost volumes [58][90] Other Important Information - The company issued $750 million of 0.75% convertible notes to reduce interest expenses and improve cash flow [6] - The data business is expected to grow at around 30% for the year, with Q4 typically being the largest revenue quarter [62] Q&A Session Summary Question: Can you elaborate on the strong core genomic volumes in the quarter? - Management noted significant sequential volume growth across oncology testing, driven by sales force efficiencies and technology improvements [12][13] Question: How should we think about the cadence of ASP as you migrate volumes to CDx? - ASPs are expected to see incremental gains as the company approaches its target of migrating 40% of XT volume to CDx by year-end [22] Question: Can you discuss bookings trends for Insights and Trials? - Bookings were strong due to the AstraZeneca Pathos deal, with total contract value up materially [30] Question: What is the pipeline for future partnerships with pharma? - The pipeline remains robust, with no significant pressure from competitors, and the company expects to close large deals in the future [39] Question: How do you balance investments among various parts of the business? - The company aims to maintain discipline in investments while focusing on long-term growth and adjusted EBITDA positivity [43][86] Question: What are the expectations for the back half of the year in the data business? - The data business is expected to grow slightly above 30% for the year, with Q4 anticipated to be the largest revenue quarter [62] Question: How is the liquid biopsy business performing? - The liquid biopsy franchise is growing faster than the market, with a competitive product set [68][70] Question: What is the company's appetite for acquisitions or partnerships? - The company remains opportunistic but disciplined in pursuing acquisitions that align with its strategic goals [78][80] Question: How significant will MRD be in the oncology volumes? - MRD is expected to become a larger part of the business once reimbursement is secured, which will drive unit growth [90][94]